Karen L Burger, Mario R Fernandez, Mark B Meads, Praneeth Sudalagunta, Paula S Oliveira, Rafael Renatino Canevarolo, Raghunandan Reddy Alugubelli, Alexandre Tungsevik, Gabe De Avila, Maria Silva, Allison I Graeter, Hongyue A Dai, Nicole D Vincelette, Antony Prabhu, Dario Magaletti, Chunying Yang, Weimin Li, Amit Kulkarni, Oliver Hampton, John M Koomen, William R Roush, Andrii Monastyrskyi, Anders E Berglund, Ariosto S Silva, John L Cleveland, Kenneth H Shain
UNLABELLED: Multiple myeloma remains an incurable malignancy due to acquisition of intrinsic programs that drive therapy resistance. Here we report that casein kinase-1δ (CK1δ) and CK1ε are therapeutic targets in multiple myeloma that are necessary to sustain mitochondrial metabolism. Specifically, the dual CK1δ/CK1ε inhibitor SR-3029 had potent in vivo and ex vivo anti-multiple myeloma activity, including against primary multiple myeloma patient specimens...
December 1, 2023: Cancer Research